代表性文章(10篇):
1. Kang Lu,1 Bo Li,1 Hui Zhang,1 Zhijian Xu, Dongliang Song, Lu Gao, Haiguo Sun, Liping Li, Yingcong Wang, Qilin Feng, Gege Chen, Liangning Hu, Rong Wei, Yongsheng Xie, Dandan Yu, Xiaosong Wu, Weiliang Zhu*, Jumei Shi*. A Novel Silicone Derivative of Natural Osalmid (DCZ0858) Induces Apoptosis and Cell Cycle Arrest in Diffuse Large B-cell Lymphoma via the JAK2/STAT3 Pathway. Signal Transduction and Targeted Therapy, 2020, 5: 31. (IF=5.873/2018, JCR 1区)
2. Gege Chen,1 Ke Hu,1 Haiguo Sun, Jinfeng Zhou, Dongliang Song, Zhijian Xu, Lu Gao, Ye Lu, Yao Cheng, Qilin Feng, Hui Zhang, Yingcong Wang, Liangning Hu, Kang Lu, Xiaosong Wu, Bo Li*, Weiliang Zhu*, Jumei Shi*. A novel phosphoramide compound, DCZ0847, displays in vitro and in vivo anti-myeloma activity, alone or in combination with bortezomib. Cancer Lett. 2020 Mar 8, 478: 45-55. (IF= 6.508/2018, JCR 1 区)
3. Yingcong Wang,1 Jing Huang,1 Bo Li,1 Han Xue, Guido Tricot, Liangning Hu, Zhijian Xu, Xiaoxiang Sun, Shuaikang Chang, Lu Gao, Yi Tao, Hongwei Xu, Yongsheng Xie, Wenqin Xiao, Dandan Yu, Yuanyuan Kong, Gege Chen, Xi Sun, Fulin Lian, Naixia Zhang, Xiaosong Wu, Zhiyong Mao, Fenghuang Zhan, Weiliang Zhu*, and Jumei Shi*. A Small Molecule Inhibitor Targeting TRIP13 suppresses multiple myeloma progression. Cancer Res. 2020 Feb 1;80(3):536-548.(IF=8.378/2018,JCR 1区)
4. Lixia Ding,1 Lu Wang,1 Kun Zou,1 Bo Li,* Yunqing Song, Qihua Zhang, Yitian Zhao, Zhijian Xu, Guangbo Ge,* Bo Zhao* and Weiliang Zhu*. Discovery of dihydrooxazolo[2,3-a]isoquinoliniums as highly specific inhibitors of hCE2. RSC Adv., 2019, 9, 35904-35912 (IF=3.049/2018)
5. Peng Liu, Bo Li,* Mengyu Xi, Zhaoqiang Chen, Haiguo Sun, Xiajuan Huan, Xuejun Xu, Yong Zhang, Kun Zou, Xiangrui Jiang, Zehong Miao, Jinggen Liu, Jingshan Shen, Kaixian Chen, Weiliang Zhu*. Metal-free quinolylation of the primary amino groups of amino acid derivatives and peptides with dihydrooxazolo[3,2-a]quinoliniums. Green Chem., 2019 July 12, 21, 4231 - 4237(IF=9.405/2018,Top期刊,JCR 1区)
6. Lu Gao,1 Bo Li,1 Guang Yang1, Peng Liu, Xiucai Lan, Shuaikang Chang, Yi Tao, Zhijian Xu, Bingqian Xie, Xi Sun, Yingcong Wang, Liangning Hu, Dandan Yu, Yongsheng Xie, Wenxuan Bu, Xiaosong Wu, Weiliang Zhu*, Jumei Shi*. Dual inhibition of mTORC1/2 by DCZ0358 induces cytotoxicity in multiple myeloma and overcomes the protective effect of the bone marrow microenvironment. Cancer Lett. 2018 May 1;421:135-144 (IF 6.491 / 2017,JCR 1区)
7. Bo Li,1 Susu Xue,1 Yang Yang,1 Jia Feng,1 Peng Liu, Yong Zhang, Jianming Zhu, Zhijian Xu, Adrian Hall, Bo Zhao,* Jiye Shi,* and Weiliang Zhu,* Regioselectivity and Mechanism of Synthesizing N-Substituted 2-Pyridones and 2-Substituted Pyridines via Metal-Free C-O and C-N Bond-Cleaving of Oxazoline[3,2-a]pyridiniums, Sci Rep. 2017 Jan 25;7:41287.(IF 4.259 / 2016)
8. Yunfei Zhou, Jianming Zhu, Bo Li,* Yong Zhang, Jia Feng, Adrian Hall, Jiye Shi,* Weiliang Zhu*. Access to Different Isomeric Dibenzoxazepinones through Copper-Catalyzed C-H Etherification and C-N Bond Construction with Controllable Smiles Rearrangement, Org Lett. 2016 Feb 5;18(3):380-383. (IF 6.732 / 2015,JCR 1区)
9. Bo Li,1 Gaihong Wang,1 Zhijian Xu, Yong Zhang, Xiangui Huang, Bubing Zeng, Kaixian Chen, Jiye Shi,* Heyao Wang,* Weiliang Zhu.* Discovery of N-substituted 3-arylisoquinolone derivatives as antitumor agents originating from O-substituted 3-arylisoquinolines via [2,3] or [3,3] rearrangement,Eur J Med Chem., 2014 Apr 22;77:204-210.(IF 3.432 / 2013)
10. Bo Li,1 Gaihong Wang,1 Mu Yang, Zhijian Xu, Bubing Zeng,* Heyao Wang,* Jingshan Shen, Kaixian Chen, Weiliang Zhu.* Overman rearrangement and PomeranzeFritsch reaction for the synthesis of benzoazepinoisoquinolones to discover novel antitumor agents,Eur. J. Med. Chem.,2013,70:677-684. (IF 3.499 / 2012)
代表性专利(10篇):
1.施菊妹,李波,陈格格,徐志建,张勇,吴晓松,朱维良,基于紫檀芪和香荚兰乙酮的偶联分子DCZ0847类化合物、其制备方法及用途,申请日:2020.02.25,申请号:CN202010116358.6,申请人:上海市第十人民医院;中国科学院上海药物研究所。
2.李波,施菊妹,徐志建,卜文宣, 张勇,陆康,朱维良,一类柳胺酚有机硅化合物及抗肿瘤用途,申请日:2019.09.05,申请号:CN201910838700.0,申请人:中国科学院上海药物研究所;上海市第十人民医院。
3.李波,刘鹏,孙海国,奚萌宇,徐志建,张勇,朱维良,一种唑啉季铵盐修饰分子中氨基的方法及用途,PCT申请日:2020.03.30,优先权日:2019.04.08,申请号:PCT/CN2020/081983,申请人:中国科学院上海药物研究所。
4.李波,谢华,刘鹏,童林江,周云飞,张勇,徐志建,施菊妹,朱维良,丁健,芳基酮酰胺类化合物及其制备方法和用途,申请日:2019.04.20,申请号:CN201910320368.9,申请人:中国科学院上海药物研究所。
5.李波,施菊妹,贺湾,徐志建,余丹丹,张勇,蔡婷婷,张鑫贲,朱维良,基于柳胺酚和紫檀芪的成环偶联分子DCZ0801类化合物及其用途,申请日:2019.02.19,申请号:CN201910122970.1,申请人:中国科学院上海药物研究所、上海市第十人民医院。
6.朱维良,施菊妹,李波,高露,刘鹏,王英聪,徐志建,张勇,蔡婷婷,一类芳基异喹啉并噁唑季铵盐类化合物、其制备方法及用途,申请日:2017.12.20,申请号:CN201711384769.8,申请人:中国科学院上海药物研究所、上海市第十人民医院。
7.朱维良,施菊妹,李波,陈格格,徐志建,张勇,胡亮凝,李钊,邹坤,蔡婷婷,陈凯先,七元环小檗碱类似物及其药物组合物在制备治疗血液肿瘤的药物中的应用,申请日:2017.02.27,申请号:CN2017101044814,申请人:中国科学院上海药物研究所、上海市第十人民医院。
8.朱维良,李波,薛溯塑,李小龙,刘鹏,张勇,徐志建,蔡婷婷,陈凯先,一类噁唑并吡啶季铵盐类化合物、其制备方法及用途,申请日:2016.08.16,公开号:CN107759614A,申请人:中国科学院上海药物研究所。
9.朱维良,施菊妹,李波,高敏杰,周云飞,陶怡,徐志建,吴慧群,张勇,芳基胍类化合物及其制备方法和用途,申请日:2016.02.26,申请号:CN201610107774.3,申请人:中国科学院上海药物研究所、上海市第十人民医院。
10.朱维良,缪泽鸿,李波,宋姗姗,徐志建,张勇,蔡婷婷,陈凯先,七元环小檗碱类似物及其药物组合物、制备方法和用途,申请日:2015.03.04,授权日:2019.12.16,专利号:CN201510096563X,申请人:中国科学院上海药物研究所。 |